Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 2101 - 2125 of 15224 in total
Lasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019.[L9338,L9356] It was also approved by the European Commission on August 17, 2022. Traditionally, the triptan class of anti-migraine medications (e.g. sumatriptan) have seen preferential use...
Approved
Investigational
Matched Description: … lability and other cardiovascular side effects - for this reason, these medications are less suitable ... seen preferential use in the acute treatment of migraines due to their relatively favourable efficacy and ... Their use is not devoid of concerns, however, and their vasoconstrictive activity can lead to blood pressure …
Clobetasol is under investigation for the treatment of Scleroderma. Clobetasol has been investigated for the prevention of Psoriasis and Cutaneous Atrophy Due to Corticosteroids.
Approved
Experimental
Investigational
Matched Description: … Clobetasol has been investigated for the prevention of Psoriasis and Cutaneous Atrophy Due to Corticosteroids …
Matched Categories: … clobetasol and antibiotics ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Binimetinib, also known as Mektovi, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with Encorafenib.[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of Encorafenib and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients...
Approved
Investigational
Matched Description: … ] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients with ... Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase ... [A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Propiverine is a widely used antimuscarinic drug with a mixed mode of action in the treatment of symptoms associated with overactive bladder (OAB) . Overactive bladder (OAB) is a chronic condition of the lower urinary tract characterized by urinary urgency, increased frequency of urination, and nocturia (frequent waking during the...
Approved
Investigational
Matched Description: … prevalence in men and women. ... OAB has a negative impact on quality of life and may lead to leakage and inconvenient urinary accidents ... Overactive bladder syndrome affects millions of elderly individuals in the United States and shows equal …
Matched Categories: … Genito Urinary System and Sex Hormones ... Drugs for Urinary Frequency and Incontinence …
Iobitridol has been used in trials studying the diagnostic of Diagnostic Imaging, Coronary Artery Disease, Type 2 Diabetes Mellitus, and Coronary Atherosclerosis.
Approved
Investigational
Matched Description: … trials studying the diagnostic of Diagnostic Imaging, Coronary Artery Disease, Type 2 Diabetes Mellitus, and
Xamoterol is a β1-adrenoceptor partial agonist that has shown to improve systolic and diastolic function in studies with heart failure patients. It modulates the sympathetic control of the heart but has no agonist action on β2-adrenoceptors.
Approved
Matched Description: … Xamoterol is a β1-adrenoceptor partial agonist that has shown to improve systolic and diastolic function …
Nomegestrol acetate, also known as NOMAC, is a progestin used in oral contraceptives, menopausal hormone therapy, and for the treatment of gynecological disorders.
Approved
Investigational
Matched Description: … acetate, also known as NOMAC, is a progestin used in oral contraceptives, menopausal hormone therapy, and
Matched Categories: … Combination Contraceptives (with Estrogen and derivatives) …
Approved
Vet approved
An antimitotic agent with immunosuppressive properties. Dexrazoxane, the (+)-enantiomorph of razoxane, provides cardioprotection against anthracycline toxicity. It appears to inhibit formation of a toxic iron-anthracycline complex. [PubChem] The Food and Drug Administration has designated dexrazoxane as an orphan drug for use in the prevention or reduction in the incidence and...
Approved
Withdrawn
Matched Description: … prevention or reduction in the incidence and severity of anthracycline-induced cardiomyopathy. ... [PubChem] The Food and Drug Administration has designated dexrazoxane as an orphan drug for use in the …
A reversible monoamine oxidase inhibitor (MAOI) selective for isoform A (RIMA) used to treat major depressive disorder. Most meta-analyses and most studies indicate that in the acute management of depression, moclobemide is more efficacious than placebo medication and similarly efficacious as tricyclic antidepressants (TCA) or selective serotonin reuptake inhibitors (SSRIs)....
Approved
Investigational
Matched Description: … Most meta-analyses and most studies indicate that in the acute management of depression, moclobemide ... is more efficacious than placebo medication and similarly efficacious as tricyclic antidepressants (TCA ... Due to negligible anticholinergic and antihistaminic actions, moclobemide has been better tolerated than …
Matched Categories: … Benzamides and benzamide derivatives …
An anti-androgen that, in the form of its acetate (cyproterone acetate), also has progestational properties. It is used in the treatment of hypersexuality in males, as a palliative in prostatic carcinoma, and, in combination with estrogen, for the therapy of severe acne and hirsutism in females.
Approved
Investigational
Matched Description: … in combination with estrogen, for the therapy of severe acne and hirsutism in females. ... It is used in the treatment of hypersexuality in males, as a palliative in prostatic carcinoma, and, …
Matched Categories: … Antiandrogens and Estrogens ... cyproterone and estrogen ... Genito Urinary System and Sex Hormones ... Sex Hormones and Modulators of the Genital System ... Combination Contraceptives (with Estrogen and derivatives) …
Peramivir is an antiviral agent developed by Biocryst Pharmaceuticals to treat influenza A/B. The development of peramivir has been supported by the US Department of Health and Human Services as part of the government's effort to prepare for a flu pandemic. Being an influenza virus neuraminidase inhibitor, peramivir works by...
Approved
Investigational
Matched Iupac: … 1S,2S,3R,4R)-4-carbamimidamido-3-[(1S)-1-acetamido-2-ethylbutyl]-2-hydroxycyclopentane-1-carboxylic acid
Matched Description: … The development of peramivir has been supported by the US Department of Health and Human Services as ... the poor oral bioavailability, the oral formulation of the drug was previously abandoned by Johnson and ... in September 2017 for the treatment of acute uncomplicated influenza to pediatric patients 2 years and
Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated...
Approved
Matched Description: … INR testing, and numerous drug-drug and drug-food interactions. ... atrial fibrillation (NVAF) and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism ... Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting …
Matched Categories: … Blood and Blood Forming Organs …
Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its ligand Substance P, which is released in the gut...
Approved
Investigational
Matched Description: … Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated ... Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and ... By blocking Substance P from interacting with NK-1 receptors in the gut and the central nervous system …
Matched Categories: … Antiemetics and Antinauseants ... Alimentary Tract and Metabolism …
Spinosad is a pediculicide mixture of spinosyn A and spinosyn D (in an approximately 5:1 ratio, respectively) used in the topical treatment of head lice in children (four years old and older) and in adults. Spinosad is an insecticide based on a compound found in S. spinosa, a bacterial species....
Approved
Investigational
Vet approved
Matched Description: … ) used in the topical treatment of head lice in children (four years old and older) and in adults. ... Spinosad is a pediculicide mixture of spinosyn A and spinosyn D (in an approximately 5:1 ratio, respectively ... Spinosad has also been experimented for use in cats for treatment of flea infestations, and has also …
Simoctocog alfa is a recombinant B-domain deleted (BDD) rFVIII produced in genetically modified human embryonic kidney (HEK) 293F cells. The harvested product is concentrated and purified by a series of chromatography steps. It is an antihemorrhagic agent used as a replacement therapy in individuals with Haemophilia A who lack the...
Approved
Matched Description: … replaced by a 16 amino acid linker. ... The harvested product is concentrated and purified by a series of chromatography steps. ... + A3-C1-C2 whereas the B-domain, present in the full-length plasma-derived FVIII, has been deleted and
Matched Categories: … Amino Acids, Peptides, and Proteins …
A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822)
Approved
Investigational
Withdrawn
Matched Description: … A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. …
Matched Categories: … hydroflumethiazide and potassium ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …
Nepafenac is a non-steroidal anti-inflammatory prodrug (NSAID) usually sold as a prescription eye drop. It is used to treat pain and inflammation associated with cataract surgery.
Approved
Investigational
Matched Description: … It is used to treat pain and inflammation associated with cataract surgery. …
Lupus nephritis (LN) is a type of glomerulonephritis occurring in patients with systemic lupus erythematosus (SLE). LN is a significant cause of renal failure, morbidity, and death in patients with SLE. Within 10 years of being diagnosed with SLE, 5-20% of those suffering from LN develop end-stage kidney disease, a...
Approved
Investigational
Matched Description: … Early and accurate intervention for LN is important in improving clinical outcomes. ... LN is a significant cause of renal failure, morbidity, and death in patients with SLE. ... [L31208] Voclosporin has demonstrated a more stable pharmacokinetic and pharmacodynamic relationship …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Frovatriptan is a triptan drug developed by Vernalis for the treatment of migraine headaches, in particular those associated with menstruation. Frovatriptan causes vasoconstriction of arteries and veins that supply blood to the head.
Approved
Investigational
Matched Description: … Frovatriptan causes vasoconstriction of arteries and veins that supply blood to the head. …
Matched Categories: … Serotonin-1b and Serotonin-1d Receptor Agonist …
Tiopronin is a prescription thiol drug used primarily in the treatment of severe homozygous cystinuria. Patients with cystinuria excrete high levels of cystine in their urine and are at risk for kidney stone formation. Tiopronin is used as a second-line therapy to control the rate of cystine precipitation and excretion,...
Approved
Investigational
Matched Iupac: … 2-(2-sulfanylpropanamido)acetic acid
Matched Description: … , and prevent kidney stone formation. ... protein, and urinary alkalinization. ... Patients with cystinuria excrete high levels of cystine in their urine and are at risk for kidney stone …
Matched Categories: … Reducing and Complexing Thiol ... Amino Acids, Peptides, and Proteins ... Genito Urinary System and Sex Hormones …
Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to cidoxepin. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepressant but...
Approved
Investigational
Matched Description: … Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. ... [L5977] Doxepin was developed by Pfizer and FDA approved in 1969 as an antidepressant. ... [T559] It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer …
Matched Categories: … Acid Reducers ... Hypnotics and Sedatives ... Antipruritics and Local Anesthetics ... Tricyclics and Other Norepinephrine-reuptake Inhibitors …
Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of thalidomide and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. However, lenalidomide is much safer and potent than thalidomide, with...
Approved
Matched Description: … and toxicities. ... exists as a racemic mixture of the active S(-) and R(+) forms. ... [A228708] However, lenalidomide is much safer and potent than thalidomide, with fewer adverse effects …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal...
Approved
Investigational
Matched Description: … Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. ... this same formulation gained additional approval in both the US and Canada in 2019 for the treatment ... a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Displaying drugs 2101 - 2125 of 15224 in total